Clinic Roundup

• Athersys Inc., of Cleveland, reported results from its Phase I trial of MultiStem in patients undergoing hematopoietic stem cell transplants (HCSTs) for leukemia and related conditions, which showed that the cell therapy product was well tolerated in both the single-infusion and repeat-infusion arms. Data also suggested that the therapy might provide benefit to patients of allogeneic HSCT, such as reducing the incidence and severity of graft-vs.-host disease (GvHD) as compared to historical clinical experience. MultiStem has orphan drug designation for the prevention of GvHD.